Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Branded formulation business continues to perform well across domestic and export markets
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Subscribe To Our Newsletter & Stay Updated